Anesiva Zingo gets fast-acting approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryFDA's Aug. 16 approval of the fast-acting topical local analgesic comes five weeks ahead of the NDA's Sept. 24 user fee goal. The needle-free Zingo system delivers 0.5 mg lidocaine powder into the epidermis of the skin, providing local analgesia one to three minutes after administration. Commonly used local anesthetics take 20 minutes or longer to act, Anesiva notes. Zingo is approved to reduce pain associated with venous access procedures, such as IV insertions or blood draws, in children ages 3 to 18. The company plans to file an sNDA broadening the label to include adults by the end of the year...
You may also be interested in...
The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.
The company maintains that its products are safe, but plaintiffs in proposed class actions allege it has knowingly put consumers at risk of hair loss and other injuries. DevaCurl’s troubles escalated quickly after a former brand ambassador went viral with a 31 January video urging consumers to stop using DevaCurl products and adopt safer alternatives.
To aid its value assessments, ICER is interested in helping FDA understand the importance of patient-relevant outcomes and consistent endpoints across trials of drugs for the same disease.